Antipodes Partners
JAZZ icon

Antipodes Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Antipodes Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$45.4K Buy
+196
New +$48.4K ﹤0.01% 122

Other funds holding JAZZ

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Antipodes Partners's JAZZ Position: Q3 2026 in Review

Antipodes Partners opened a new position in Jazz Pharmaceuticals (JAZZ) in Q3 2026: 196 shares worth $45.4K. The stake represents ﹤0.01% of the portfolio and ranks #122 among its holdings.

538 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • Antipodes Partners held 196 shares of Jazz Pharmaceuticals worth $45.4K as of Q3 2026.
  • Jazz Pharmaceuticals was a new Antipodes Partners position in Q3 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Antipodes Partners's portfolio in Q3 2026, its #122 holding.
  • 538 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Antipodes Partners's 13F filing for Q3 2026, filed 5 Nov 2026.